The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Learning Center / Antibody Validation Webinar Series

Antibody Validation Webinar Series

Tool antibodies are the dominant affinity reagent for proteomics in cell biology, reflected by the over 4.5 million antibodies that are commercially available. Distinct from therapeutics or diagnostics, tool antibodies tend to be poorly characterized. This is echoed by many reports of catastrophic specificity, activity, identity and reporting deficits involving such reagents.

Nevertheless, biological sciences remain highly dependent on them.

In this 10-part series, aimed especially at those beginning a career in biological sciences, The Antibody Society has invited leaders in antibody research from industry and academia to reflect on antibody validation. They paint a uniformly alarming picture of inadequacies at many levels – which encourages users to be highly aware of the consequences of inadequate tool antibody validation, which threaten their biological endeavors.

Moderator: Dr. Simon Goodman, Science & Technology Program Manager, The Antibody Society

Broadcast dates: November 12, 2019 – February 19, 2020.

#1: Antibody specificity? What’s the problem

In this introduction to the topic, Professor Andreas Plückthun, University of Zürich, discusses the biology of the 3 principal types of commercial antibodies: polyclonal, monoclonal, and recombinant. Surprisingly, only recombinants offer a reasonable hope of reproducibility in the long term – yet they remain very much the minority.

Speaker: Dr. Andreas Plückthun

View On-Demand Recording

View Dr. Plückthun’s Presentation Slides

View Questions and Answers from the live Webinar 1


#2: Antibodies drive irreproducibility

Professor Glenn Begley, Biocurate Pty Ltd, and Professor Cecilia Williams, KTH Royal Institute of Technology, describe arduous, alarming and very costly experiences in failing to confirm “well established” critical data in oncology – a failure often driven by ineptly characterized antibodies.

Speakers: Dr. Glenn Begley and Dr. Cecilia Williams

View On-Demand Recording

View Dr. Begley’s Presentation Slides     View Dr. Williams’ Presentation Slides

View Questions and Answers from the live Webinar 2


#3: What’s in a name? Finding the antibody for the job

Dr. Jan Voskuil, Aeonian Biotech, and Professor Andy Chalmers, University of Bath and CiteAb, delve into the mysterious world of  the original equipment manufacturers (OEMs), which can veil the identity of antibodies, and data-base repositories that help unveil which antibody has produced reliable results.

Speakers: Dr. Jan Voskuil and Dr. Andrew Chalmers

View On-Demand Recording

View Dr. Voskuil’s Presentation Slides     View Dr. Chalmers’ Presentation Slides

View Questions and Answers from the live Webinar 3


#4: What is this antibody?

Professor Anita Bandrowski, University California San Diego and SciCrunch, and Dr. Jan Voskuil, Aeonian Biotech, probe how antibody reagents are identified. If we can’t identify which antibody has been used, we can never reproduce experiments. The Research Reagent Identifier systematically tags antibodies so they can be tracked, but the small-print on the data-sheets still hides many things.

Speakers: Dr. Jan Voskuil and Dr. Anita Bandrowski

View On-Demand Recording

View Dr. Voskuil’s Presentation Slides     View Dr. Bandrowski’s Presentation Slides

View Questions and Answers from the live Webinar 4


#5: Really? Out of control(s)?

Dr. Giovanna Roncador, Centro Nacional de Investigaciones Oncológicas and EuroMabNet, examines the criticality of using appropriate fit-for-purpose controls, both positive and negative, to validate antibodies in every experimental context.

Speaker: Dr. Giovanna Roncador

View On-Demand Recording

View Dr. Roncador’s Presentation Slides

View Questions and Answers from the live Webinar 5


#6: Even the Easy Stuff Isn’t

Professors Aldrin Gomes and James Trimmer, both from University of California, Davis, dissect two “basic” validation technologies, Western blot and immunohistochemistry, to expose the very many things that can distort validation data.

Speakers: Dr. Aldrin Gomes and Dr. James Trimmer

View On-Demand Recording

View Dr. Gomes’ Presentation Slides     View Dr. Trimmer’s Presentation Slides

View Questions and Answers from the live Webinar 6


#7: It’s a Knockout

Travis Hardcastle, Horizon, and Dr. Alejandra Solache, Abcam, describe the character of different gene-knockout technologies, one of the strongest validation technologies, and their value in large-scale antibody screening.

Speakers: Dr. Travis Hardcastle and Dr. Alejandra Solache

View On-Demand Recording

View Travis Hardcastle’s Presentation Slides     View Dr. Solache’s Presentation Slides

View Questions and Answers from the live Webinar 7


#8: Protein Arrays and Mass Spectrometry

Dr. Mike Taussig, Cambridge Protein Arrays, and Dr. Fridtjof Lund-Johansen, Oslo University Hospital, look at array and immunoprecipitation-mass spectrometry technologies, which offer a broader and deeper image of antibody specificity and selectivity for validation, than classical validation technologies.

Speakers: Dr. Mike Taussig and Dr. Fridtjof Lund-Johansen

View On-Demand Recording

View Dr. Taussig’s Presentation Slides     View Dr. Lund-Johansen’s Presentation Slides

View Questions and Answers from the live Webinar 8


#9: Getting to Recombinant Antibodies that Guarantee Reproducible Research

Dr. Andrew Bradbury, Specifica, suggests ways out of the validation maze by rigorous molecular identification of recombinant tool antibodies. This achievable goal could eliminate many of the shadowy issues described in this series of webinars.

Speaker: Dr. Andrew Bradbury

View On-Demand Recording

View Dr. Bradbury’s Presentation Slides

View Questions and Answers from the live Webinar 9


#10: Specific Detection Reagents: What’s the Future?

Future recombinant binding tools may avoid antibodies, and use diversified libraries based on small and versatile protein scaffolds, for example the DARPins (Designed Ankyrin Repeat Proteins).  DARPins are single-chain, monodisperse, and non-immunogenic, and can be made rapidly and cheaply in bacteria in many formats.  They can also be expressed in and on cells as non-aggregating fusion proteins with tunable valencies, which opens a wide range of previously- inaccessible approaches in cell biology and biochemistry.

Speaker: Dr. Andreas Plückthun 

View On-Demand Recording

View Prof. Plückthun’s Presentation Slides

View Questions and Answers from the live Webinar 10


All Antibody Society webinars are open access,
and can be viewed for free.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • The Antibody Society announces the election of new Directors and Officers January 26, 2023
  • AIRR Data Commons and iReceptor Science Gateway Start Major Collaboration with Type-1 Diabetes Researchers January 11, 2023
  • FDA approves Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease January 6, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals